High Risk and Very High Risk MDS Completed Phase 1 Trials for Alpelisib (DB12015)

IndicationStatusPhase
DBCOND0091622 (High Risk and Very High Risk MDS)Completed1
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT01449058A Phase Ib Study of MEK162 Plus BYL719 in Adult Patients With Selected Advanced Solid TumorsTreatment